Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG

• US 20150065449A1
• Filed: 11/12/2014
• Published: 03/05/2015
• Est. Priority Date: 08/12/2011
• Status: Abandoned Application

• Current Assignee: Florida State University Research Foundation, Inc. (State University System of Florida)
• Original Assignee: Florida State University Research Foundation, Inc. (State University System of Florida)
• Inventors: Bienkiewicz, Ewa Anna
• Application Number:
  US14/539,515
• Publication Number:
  US 20150065449A1
• Time in Patent Office: Days
• US Class Current: 514/52
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/4045 Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• CPC Class Codes: A61K 31/714 Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants

Abstract

A method of treating amyloid-beta peptide aggregation in a subject includes contacting at least one amyloid-beta peptide oligomer formed from a plurality of amyloid-beta peptide monomers with a composition containing melatonin, resveratrol, EGCG, and an effective amount of vitamin B12. The effective amount of vitamin B12 being sufficient to stimulate dissociation of the amyloid-beta peptide monomers from the at least one amyloid-beta peptide oligomer. The composition may be used to treat amyloidosis, including Alzheimer'"'"'s disease.

Claims

1. A method of treating amyloid-beta peptide aggregation in a human having Alzheimer'"'"'s disease, the method comprising:

determining a first level of amyloid-beta peptides in the human;

establishing a first dose of vitamin B12 based on the first level of amyloid-beta peptides in the human, the first dose being sufficient to cause dissociation of amyloid-beta peptide monomers from amyloid-beta peptide aggregates in the human; and

administering a pharmaceutically acceptable dosage form to the human, the dosage form containing the first dose of vitamin B12 in combination with melatonin, resveratrol, and EGCG.

2. The method of claim 1, wherein determining the first level of amyloid-beta peptides in the human includes testing the human'"'"'s plasma for an amount of amyloid-beta peptides therein.

3. The method of claim 1, wherein the amount of vitamin B12 in the first dose is at least equimolar with a molarity of amyloid-beta peptides in the first level of amyloid-beta peptides.

4. The method of claim 1, further comprising:

determining a second level of amyloid-beta peptides in the human after administering the first dose;

establishing a second dose of vitamin B12 based on the second level of amyloid-beta peptides in the human; and

administering the second dose to the human.

5. The method of claim 4, wherein the amount of vitamin B12 in the second dose is at least equimolar with a molarity of amyloid-beta peptides in the second level of amyloid-beta peptides.

6. A method of treating amyloid-beta peptide aggregation in a subject, the method comprising contacting at least one amyloid-beta peptide oligomer formed from a plurality of amyloid-beta peptide monomers with a composition containing melatonin, resveratrol, EGCG, and an effective amount of vitamin B12, the effective amount of vitamin B12 being sufficient to stimulate dissociation of the amyloid-beta peptide monomers from the at least one amyloid-beta peptide oligomer.

7. The method of treating amyloid-beta peptide aggregation of claim 6, wherein the effective amount is a function of a quantity of amyloid-beta peptides in a sample taken from the subject.

8. The method of treating amyloid-beta peptide aggregation in a subject of claim 7, wherein the sample is a portion of the subject'"'"'s plasma.

9. The method of treating amyloid-beta peptide aggregation in a subject of claim 7, wherein the effective amount is at least equimolar with a molarity of amyloid-beta peptides estimated to be in the subject based on the quantity of amyloid-beta peptides in the sample.

10. The method of treating amyloid-beta peptide aggregation in a subject of claim 6, wherein the effective amount is at least one molecule of vitamin B12 per amyloid-beta peptide monomer dissociated.

11. The method of treating amyloid-beta peptide aggregation in the subject of claim 6, wherein the subject is identified as having a condition characterized by amyloid-beta peptide aggregates.

12. A method of treating Alzheimer'"'"'s disease, the method comprising administering to a human having Alzheimer'"'"'s disease a pharmaceutically acceptable dosage form containing melatonin, resveratrol, EGCG, and an effective amount of vitamin B12, the effective amount of vitamin B12 being sufficient to cause dissociation of amyloid-beta peptide monomers from pre-existing amyloid-beta peptide oligomers in the human, the effective amount being based on a pre-determined quantity of amyloid-beta peptide oligomers in the human.

13. The method of treating Alzheimer'"'"'s disease of claim 12, wherein the quantity of amyloid-beta peptide oligomers in the patient is estimated from a level of amyloid-beta peptides in a sample of the patient'"'"'s plasma.

14. The method of treating Alzheimer'"'"'s disease of claim 13, wherein the effective amount is at least an equimolar ratio of vitamin B12 to amyloid-beta peptides in the sample.

15. A method of treating an amyloidosis, the method comprising:

administering to a human having an amyloidosis a pharmaceutically acceptable dosage form containing melatonin, resveratrol, EGCG, and an effective amount of vitamin B12, the effective amount of vitamin B12 being sufficient to cause dissociation of amyloid-beta peptide monomers from pre-existing amyloid-beta peptide oligomers in the human.

16. The method of claim 15, wherein the effective amount of vitamin B12 is a function of a pre-determined quantity of amyloid-beta peptide oligomers in the human.

17. The method of claim 15, wherein the quantity of amyloid-beta peptide oligomers in the human is estimated from a level of amyloid-beta peptides in a sample of the human'"'"'s plasma.

18. The method of claim 15, wherein the effective amount of vitamin B12 is at least an equimolar ratio of vitamin B12 to amyloid-beta peptides in a sample of the human'"'"'s plasma.

19. The method of claim 15, wherein the amyloidosis is Alzheimer'"'"'s disease.